Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors.
Maximilian GassenmaierMax M LendersAndrea ForschnerUlrike LeiterBenjamin WeideClaus GarbeThomas K EigentlerNikolaus Benjamin WagnerPublished in: Targeted oncology (2021)
LDH and S100B are suitable serum biomarkers during therapy with BRAFi. S100B shows stronger correlation with response and exhibits more accuracy in predicting PD. Close biomarker monitoring with S100B is recommended during treatment with BRAFi to detect PD early.